border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your filings are automatically published to your site as they are filed.
  • Investors don't have to leave your site to see filings.


    • Product Description
  • Once a report has been filed with the SEC it will be available on the website.


    • SEC Filings Section 16 Filings Only
     
    NOVADEL PHARMA INC filed this 424B3 on 07/16/2008.
    Click on link to view section or document
    1. Entire Document including Exhibit(s)
    2. 424B3
    PAGE: 1 - Filed pursuant to Rule 424(b)(3)
    PAGE: 2 - TABLE OF CONTENTS
    PAGE: 3 - PROSPECTUS SUMMARY
    PAGE: 4 -
    PAGE: 5 - About the Initial Closing
    PAGE: 6 -
    PAGE: 7 - About the Subsequent Closing
    PAGE: 8 -
    PAGE: 9 - About the 8,000,000 shares subject to registration under this Registration Statement
    PAGE: 10 -
    PAGE: 11 - About NovaDel
    PAGE: 12 - Product Pipeline
    PAGE: 13 - NitroMist (nitroglycerin lingual aerosol)
    PAGE: 14 - ZolpiMist (zolpidem oral spray)
    PAGE: 15 - Tizanidine oral spray
    PAGE: 16 - Veterinary.
    PAGE: 17 - THE OFFERING
    PAGE: 18 - RISK FACTORS
    PAGE: 19 - WE ARE A PRE-COMMERCIALIZATION COMPANY, HAVE A LIMITED OPERATING HISTORY AND HAVE NOT GENERATED ANY
    PAGE: 20 - OUR ADDITIONAL FINANCING REQUIREMENTS COULD RESULT IN DILUTION TO EXISTING STOCKHOLDERS.
    PAGE: 21 - THERE ARE CERTAIN INTERLOCKING RELATIONSHIPS AND POTENTIAL CONFLICTS OF INTEREST.
    PAGE: 22 - OUR BUSINESS AND REVENUE IS DEPENDENT ON THE SUCCESSFUL DEVELOPMENT OF OUR PRODUCTS.
    PAGE: 23 - WE HAVE NOT COMPLETED PRODUCT DEVELOPMENT.
    PAGE: 24 - WE ARE DEPENDENT ON OUR SUPPLIERS.
    PAGE: 25 - COMPLIANCE WITH CHANGING REGULATION OF CORPORATE GOVERNANCE AND PUBLIC DISCLOSURE MAY RESULT IN ADDI
    PAGE: 26 - LIMITED PRODUCT LIABILITY INSURANCE COVERAGE MAY AFFECT OUR BUSINESS.
    PAGE: 27 - WE EXPECT TO FACE UNCERTAINTY OVER REIMBURSEMENT AND HEALTHCARE REFORM.
    PAGE: 28 - IF WE CANNOT PROTECT OUR INTELLECTUAL PROPERTY, OTHER COMPANIES COULD USE OUR TECHNOLOGY IN COMPETIT
    PAGE: 29 - EVEN IF WE OBTAIN PATENTS TO PROTECT OUR PRODUCTS, THOSE PATENTS MAY NOT BE SUFFICIENTLY BROAD AND O
    PAGE: 30 - INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES COULD LIMIT OUR ABILITY TO MARKET OUR PRODUCTS.
    PAGE: 31 - WE ARE DEPENDENT ON EXISTING MANAGEMENT AND BOARD MEMBERS.
    PAGE: 32 - WE ARE INFLUENCED BY CURRENT STOCKHOLDERS, OFFICERS AND DIRECTORS.
    PAGE: 33 - BECAUSE THE AVERAGE DAILY TRADING VOLUME OF OUR COMMON STOCK IS LOW, THE ABILITY TO SELL OUR SHARES
    PAGE: 34 - SHARES ELIGIBLE FOR FUTURE SALE MAY ADVERSELY AFFECT THE MARKET.
    PAGE: 35 - LIMITATION ON DIRECTOR/OFFICER LIABILITY.
    PAGE: 36 - THE SECURITIES ISSUED IN OUR DECEMBER 2006 PRIVATE PLACEMENT ARE RESTRICTED SECURITIES.
    PAGE: 37 - WE MAY BE OBLIGATED, UNDER CERTAIN CIRCUMSTANCES, TO PAY LIQUIDATED DAMAGES TO HOLDERS OF OUR COMMON
    PAGE: 38 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    PAGE: 39 -
    PAGE: 40 - PLAN OF DISTRIBUTION
    PAGE: 41 - LEGAL MATTERS
    PAGE: 42 -
    PAGE: 43 - INFORMATION INCORPORATED BY REFERENCE
    PAGE: 44 - 8,000,000 Shares of Common Stock




    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol NVDL
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer